Skip to main content
Proper Name
Influenza Vaccine, Live, Intranasal (Trivalent, Types A and B)
For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Key Regulatory Milestones

06/2003 - FluMist was approved for use in healthy subjects 5-49 years of age 

01/2006 - formulation change was approved

09/17/2007 - Extension of the indication to individuals 2 – < 60 months was approved

07/09/2020 - FDA approval date

Advisory Committee

The Vaccines and Related Biologics Advisory Committee (VRBPAC) was not convened to discuss this supplement. Advice from VRBPAC was not thought to be critical to the review because the data and proposed changes to labeling do not affect the indication or use of the vaccine or reveal major safety concerns

Advanced Facts